Supply / Manufacturing · Southeast Asia · Announced 27 Oct 2026
Kimia Farma → Open to partners
Indonesia's state-owned Kimia Farma is offering domestic and foreign drugmakers contract manufacturing on 24 production lines, with planned capacity of up to 4.18 billion units a year. This is an open offer: no partner or agreement has been announced.
Parties: Kimia Farma (Indonesia) → Open to partners (none named)
- Deal type
- Supply / Manufacturing
- Value
- Undisclosed
- Territory
- Indonesia; offered to domestic and foreign pharmaceutical companies at IPEX 2026 (Jakarta, 20–23 Oct)
- Therapeutic area
- Other
- Asset
- Contract manufacturing capacity (24 production lines)
- Announced
- 27 Oct 2026
Our analysis
Why this matters
PT Kimia Farma (Persero) Tbk used the Indonesia Pharmaceutical Expo (IPEX) 2026 in Jakarta, held 20–23 October, to offer contract manufacturing partnerships to domestic and foreign pharmaceutical companies, ANTARA reported on 27 October 2026. The offer runs through its Toll Manufacturing unit and subsidiaries PT Sinkona Indonesia Lestari and PT Kimia Farma Sungwun Pharmacopia. It covers 24 production lines with planned capacity of up to 4.18 billion units a year. No partner has been named and no agreement has been signed. This entry records a partnering offer, not a completed deal.
For BD directors seeking an Indonesian entry route: a state-owned manufacturer is offering its own marketing authorisations for use under partner brands, which could shorten time to market in a market where local manufacturing is strongly favoured.
The full analysis is free to read with a work email on this page.
Source: ANTARA News